Yanuar Dwi Putra Limasale et al.
International journal of pharmaceutics, 479(2), 364-373 (2015-01-18)
Cyclooxygenase-2 (COX-2) is highly expressed in many different cancers. Therefore, the inhibition of the COX-2 pathway by a selective COX-2 inhibitor, celecoxib (CLX), may be an alternative strategy for cancer prevention and therapy. Liposomal drug delivery systems can be used